Peptides have the majority.
What’s happening: A panel of FDA advisors voted to allow pharmacies to compound six peptides, opening a legal pathway for mass distribution.
Majority rules. The committee backed BPC-157, MOTS-c, KPV, epitalon, semax, and TB-500 after evaluating use cases for ulcerative colitis, wound healing, obesity, and more. It rejected emideltide, a peptide for sleep disorders, but the FDA retains final say.
Great debate. Speaking at the hearing, Hims CMO Dr. Anant Vinjamoori conceded the evidence for peptides is “thin” but argued regulated prescribing is preferable to unsupervised use. On X, physician-scientist Eric Topol called the vote “baseless,” warning it legitimizes therapies without clinical evidence.
Head start. Already popular with gym-goers and longevity-seekers, BPC-157 and MOTS-c have fueled a multibillion-dollar gray market. Preparing for regulated access, Dr. Vinjamoori told the committee Hims “intends to offer peptide therapy if allowed,” while telehealth platforms are already positioned to prescribe at scale.
Punchline: Merely a formality, the peptide market is already here. Now, the FDA is deciding who gets to participate.
